Results 51 to 60 of about 359,969 (343)
Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts [PDF]
, 2019 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Objectives To assess predictive factors for rheumatoid arthritis interstitial lung disease (RA-ILD) in two early ...
Busby, Amanda +7 more
core +3 more sources
Arthritis Care &Research, EarlyView.As many patients with inflammatory arthritis (IA) have chronic pain, understanding how to best assess and manage pain in IA is a priority. Comorbid depression is prevalent in adults with IA, affecting 15% to 39% of people. Although pain and depression are thought to be associated in IA, this concept is largely based on cross‐sectional data.
Natasha Cox +3 more
wiley +1 more source
PLoS ONE, 2013 BackgroundMethotrexate is a chemotherapeutic agent used to treat a variety of cancers. However, the occurrence of resistance limits its effectiveness. Cytochrome c in its reduced state is less capable of triggering the apoptotic cascade.
Susana Barros +6 more
doaj +1 more source
Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures [PDF]
, 2016 Objective To describe changes in immune parameters observed during long-term methotrexate (MTX) therapy in patients with active rheumatoid arthritis (RA) and explore correlations with simultaneously measured MTX pharmacokinetic (PKC) parameters ...
Hamilton, Robert +3 more
core +1 more source
Metabolic Consequences of Rheumatoid Arthritis
Arthritis Care &Research, EarlyView.Patients with rheumatoid arthritis (RA) may have metabolic disruption, which can contribute to adverse long‐term outcomes, for multiple reasons. Patients with RA appear to have a higher risk of sarcopenia, type 1 and type 2 diabetes mellitus, metabolic syndrome, and hypertension. Systemic inflammation in RA can cause a “lipid paradox,” with reduced low‐
Stevie Barry +2 more
wiley +1 more source
Arquivos de Gastroenterologia, 2011 CONTEXT: Methotrexate and other anticancer agents can induce intestinal mucositis, which is one of the most common limiting factor that prevent further dose escalation of the methotrexate. OBJECTIVES: To evaluate the gastric emptying and gastrointestinal
Pedro M. G. Soares +5 more
doaj +1 more source
Histopathological effects of Methotrexate in mice livers [PDF]
Kirkuk Journal of Science, 2014 Background:Methotrexate is a folic acid antagonists that inhibits dihydrofolate reductase, resulting in a block in the synthesis of thymidine and inhibition of DNA synthesis. Methotrexate has been used for the treatment of malignancy, rheumatic disorders,
Asal A. Tawfeeq Sundus M. Taifoor
doaj +1 more source
Arthritis Care &Research, EarlyView.Objective Gastrointestinal perforation (GIP) is a rare and life‐threatening safety concern associated with JAK inhibitors (JAKi). We aimed to review the evidence regarding the risk of GIP associated with the use of JAKi in patients with rheumatoid arthritis (RA) using a systematic review and network meta‐analysis approach.
Thipsukhon Sathapanasiri +7 more
wiley +1 more source
EFFICACY OF FUROSEMIDE IN METHOTREXATE CLEARANCE IN PATIENTS TREATED WITH HIGH DOSE METHOTREXATE
Hematology, Transfusion and Cell Therapy, 2022 Objective: Methotrexate was first used in 1947 as a chemotherapeutic drug in the treatment of acute lymphoblastic leukemia (ALL). Methotrexate has been extensively explored as an anticancer drug since that time.
Saqib Khan +2 more
doaj
Journal of the American Medical Association (JAMA), 2019 Importance Methotrexate and mycophenolate mofetil are commonly used immunomodulatory therapies for achieving corticosteroid-sparing control of noninfectious uveitis, but there is uncertainty about which drug is more effective.
S. Rathinam +16 more
semanticscholar +1 more source